ADMA Biologics (NASDAQ:ADMA) Trading Up 4.4% - What's Next?

Key Points

• ADMA Biologics' stock rose by 4.4% during trading, reaching a high of $15.33 before closing at $15.37, despite a significant drop in trading volume.
• Wall Street analysts maintain a positive outlook, with a consensus rating of "Buy" and an average price target of $27.67.
• For the recent quarter, ADMA Biologics reported earnings per share of $0.15, exceeding estimates and showing a year-over-year revenue growth of 13.8%.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) shot up 4.4% during trading on Wednesday . The stock traded as high as $15.33 and last traded at $15.37. 850,391 shares traded hands during trading, a decline of 73% from the average session volume of 3,153,857 shares. The stock had previously closed at $14.72.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a "buy (b-)" rating on shares of ADMA Biologics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $27.67.

ADMA Biologics Stock Up 3.4%

The firm has a market cap of $3.63 billion, a price-to-earnings ratio of 17.69 and a beta of 0.47. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The firm has a 50 day moving average price of $15.92 and a 200-day moving average price of $18.31.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. During the same period last year, the firm posted $0.13 EPS. The firm's revenue for the quarter was up 13.8% on a year-over-year basis. On average, equities analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Institutional Trading of ADMA Biologics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. raised its stake in ADMA Biologics by 13.9% in the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock valued at $255,279,000 after purchasing an additional 1,570,649 shares during the last quarter. State Street Corp raised its position in shares of ADMA Biologics by 5.6% in the second quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company's stock valued at $219,950,000 after buying an additional 637,727 shares during the last quarter. Geode Capital Management LLC raised its position in shares of ADMA Biologics by 4.3% in the second quarter. Geode Capital Management LLC now owns 5,913,121 shares of the biotechnology company's stock valued at $107,691,000 after buying an additional 245,309 shares during the last quarter. Nuveen LLC purchased a new position in shares of ADMA Biologics during the first quarter valued at approximately $93,543,000. Finally, American Century Companies Inc. boosted its position in ADMA Biologics by 8.4% during the second quarter. American Century Companies Inc. now owns 4,610,989 shares of the biotechnology company's stock worth $83,966,000 after acquiring an additional 358,627 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.